Association of diabetic retinopathy with kidney disease progression according to baseline kidney function and albuminuria status in individuals with type 2 diabetes

被引:0
|
作者
Mori, Tomomi [1 ]
Hanai, Ko [1 ]
Yamamoto, Yui [1 ]
Yoshida, Naoshi [1 ]
Murata, Hidekazu [1 ]
Nakagami, Tomoko [1 ]
机构
[1] Tokyo Womens Med Univ, Sch Med, Dept Internal Med, Div Diabetol & Metab, 8-1 Kawada Cho,Shinjuku Ku, Tokyo 1628666, Japan
关键词
Diabetic retinopathy; Diabetic nephropathy; Diabetic kidney disease; Chronic kidney disease; FUNCTION DECLINE; RISK; MICROALBUMINURIA; POPULATION; PREDICTION; MORTALITY; MELLITUS; PEOPLE;
D O I
10.1007/s10157-024-02599-z
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background Whether diabetic retinopathy (DR) can predict kidney disease progression in individuals with diabetes remains unclear. Furthermore, there are only a limited number of studies investigating the association between DR and kidney outcomes classified according to baseline kidney function and albuminuria status. Here, we examined the association of DR with kidney disease progression in individuals with type 2 diabetes. Methods This retrospective cohort study included 6759 Japanese adults with type 2 diabetes (36.3% women). Kidney insufficiency and albuminuria were defined as eGFR < 60 mL/min/1.73 m2 and urinary albumin-to-creatinine ratio >= 30 mg/g, respectively. The exposure and outcome were baseline DR and the composite of eGFR halving or the initiation of kidney replacement therapy, respectively. The hazard ratios for the outcome were estimated using the multivariable Cox proportional hazards model. Results During the median follow-up period of 8.4 years, 922 reached the outcome. Among the individuals without kidney insufficiency, those with DR at baseline had a significantly higher incidence of the outcome than those without DR regardless of baseline albuminuria status (p < 0.05), whereas the presence of DR was not the risk factor among individuals with kidney insufficiency. There was an interaction between baseline DR and kidney insufficiency with respect to the outcome incidence (p = 0.043). When baseline eGFRs were classified into eGFR categories based on the Kidney Disease: Improving Global Outcomes guideline, the above findings were more clearly shown. Conclusions DR may be able to predict kidney disease progression only among individuals with type 2 diabetes exhibiting preserved kidney function.
引用
收藏
页码:607 / 615
页数:9
相关论文
共 50 条
  • [21] Diabetic kidney disease: the kidney disease relevant to individuals with diabetes
    Kanasaki, Keizo
    Ueki, Kohjiro
    Nangaku, Masaomi
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2024, 28 (12) : 1213 - 1220
  • [22] Association of Eating Patterns and Diabetic Kidney Disease in Type 2 Diabetes
    Rodrigues, Cintia C. R.
    Riboldi, Barbara P.
    Rodrigues, Ticiana C.
    Sarmento, Roberta A.
    Antonio, Juliana P.
    Borba, Raquel A.
    Vieira, Adriele P.
    Pasini, Isadora S.
    De Almeida, Jussara C.
    DIABETES, 2021, 70
  • [23] Albuminuria Is More Closely Associated with Vascular Endothelial Function than eGFR in Type 2 Diabetes with Diabetic Kidney Disease
    Kakutani, Yoshinori
    Emoto, Masanori
    Yamazaki, Yuko
    Motoyama, Koka
    Morioka, Tomoaki
    Mori, Katsuhito
    Fukumoto, Shinya
    Shioi, Atsushi
    Shoji, Tetsuo
    Inaba, Masaaki
    DIABETES, 2018, 67
  • [24] Serum proBNP predicts a decline in kidney function independently of type 2 diabetes, the baseline kidney function and baseline coronary artery disease
    Saely, C. H.
    Lins, C.
    Zanolin, D.
    Leiherer, A.
    Vonbank, A.
    Schuler, A.
    Schwerzler, P.
    Mader, A.
    Muendlein, A.
    Rein, P.
    Drexel, H.
    WIENER KLINISCHE WOCHENSCHRIFT, 2017, 129 : S63 - S63
  • [25] Serum proBNP predicts a decline in kidney function independently of type 2 diabetes, the baseline kidney function and baseline coronary artery disease
    Saely, C. H.
    Lins, C.
    Zanolin, D.
    Leiherer, A.
    Vonbank, A.
    Mader, A.
    Larcher, B.
    Muendlein, A.
    Drexel, H.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2018, 48 : 154 - 154
  • [26] Serum proBNP Predicts a Decline in Kidney Function Independently of Type 2 Diabetes, the Baseline Kidney Function, and Baseline Coronary Artery Disease
    Saely, Christoph H.
    Lins, Christina
    Zanolin, Daniela
    Leiherer, Andreas
    Vonbank, Alexander
    Schuler, Alexander
    Ebner, Karl-Martin
    Muendlein, Axel
    Rein, Philipp
    Drexel, Heinz
    DIABETES, 2017, 66 : A404 - A404
  • [27] Serum proBNP predicts a decline in kidney function independently of Type 2 diabetes, the baseline kidney function and baseline coronary artery disease
    Saely, Christoph
    Lins, Christina
    Zanolin, Daniela
    Leiherer, Andreas
    Vonbank, Alexander
    Ebner, Karl-Martin
    Schwerzler, Peter
    Mader, Arthur
    Heinzle, Christine
    Muendlein, Axel
    Drexel, Heinz
    WIENER KLINISCHE WOCHENSCHRIFT, 2017, 129 : 167 - 168
  • [28] Serum proBNP predicts a decline in kidney function independently of type 2 diabetes, the baseline kidney function and baseline coronary artery disease
    Saely, Christoph
    Lins, Christina
    Zanolin, Daniela
    Leiherer, Andreas
    Vonbank, Alexander
    Schuler, Alexandra
    Ebner, Karl-Martin
    Schwerzler, Peter
    Mader, Arthur
    Muendlein, Axel
    Rein, Philipp
    Drexel, Heinz
    WIENER KLINISCHE WOCHENSCHRIFT, 2017, 129 : S120 - S120
  • [29] EFFECTS OF SGLT2 INHIBITORS ON STROKE IN TYPE 2 DIABETES ACCORDING TO BASELINE KIDNEY FUNCTION
    Zhou, Zien
    Jardine, Meg
    Heerspink, Hiddo
    Neuen, Brendon
    Li, Qiang
    Arnott, Clare
    Mahaffey, Kenneth
    Perkovic, Vlado
    Neal, Bruce
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 221 - 221
  • [30] Combined changes in albuminuria and kidney function and subsequent risk for kidney failure in type 2 diabetes
    Oshima, Megumi
    Toyama, Tadashi
    Hara, Akinori
    Shimizu, Miho
    Kitajima, Shinji
    Iwata, Yasunori
    Sakai, Norihiko
    Furuichi, Kengo
    Haneda, Masakazu
    Babazono, Tetsuya
    Yokoyama, Hiroki
    Iseki, Kunitoshi
    Araki, Shin-ichi
    Ninomiya, Toshiharu
    Hara, Shigeko
    Suzuki, Yoshiki
    Iwano, Masayuki
    Kusano, Eiji
    Moriya, Tatsumi
    Satoh, Hiroaki
    Nakamura, Hiroyuki
    Makino, Hirofumi
    Wada, Takashi
    BMJ OPEN DIABETES RESEARCH & CARE, 2021, 9 (01)